Evidence map›Paper›PMID 42443557›Full record

ArticleWiener klinische Wochenschrift2026

Pulmonary tularemia leading to a relapse of tularemia orchitis in a patient on TNF-alpha inhibitor.

Robert Westhofen, Florian Heger, Alexey Pryalukhin, Thomas-Matthias Scherzer, Alexander Daxecker, Marek Kozák, Wolfgang Hulla, Lukas Antonitsch

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert WesthofenDepartment of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria. robert.westhofen@dp-uni.ac.at.ORCID http://orcid.org/0009-0001-2596-0839
Florian HegerInstitute for Microbiology, Austrian Agency for Health and Food Safety GmbH (AGES), Währinger Straße 25A, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-1910-2993
Alexey PryalukhinDepartment of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.ORCID http://orcid.org/0000-0003-0837-8326
Thomas-Matthias ScherzerDepartment of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.ORCID http://orcid.org/0009-0001-4234-5424
Alexander DaxeckerDepartment of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.ORCID http://orcid.org/0009-0008-2793-9778
Marek KozákDepartment for Pathology, University Hospital Wiener Neustadt, Corvinusring 3-5, 2700, Wiener Neustadt, Austria.ORCID http://orcid.org/0009-0004-5775-5831
Wolfgang HullaDepartment for Pathology, University Hospital Wiener Neustadt, Corvinusring 3-5, 2700, Wiener Neustadt, Austria.ORCID http://orcid.org/0000-0001-8189-4621
Lukas AntonitschDepartment of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.ORCID http://orcid.org/0000-0002-7590-2995

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTularemia represents a zoonotic infection that poses particular diagnostic and therapeutic challenges in immunocompromised patients. We present a rare case of tularemia orchitis in a patient receiving tumor necrosis factor alpha (TNF alpha) inhibitor treatment.

methodsWe conducted a case analysis of a 71-year-old farmer receiving adalimumab for psoriatic arthritis who developed sequential pulmonary and genitourinary manifestations of tularemia. Clinical presentation, laboratory findings, microbiological identification through culture and polymerase chain reaction testing, imaging studies, and histopathological examination were documented. Treatment response and clinical follow-up were monitored throughout the disease course.

resultsThe patient initially presented with pneumonic tularemia confirmed by positive blood cultures. Following apparent clinical resolution with doxycycline therapy, he developed orchitis 3 months later requiring unilateral orchiectomy. Polymerase chain reaction testing confirmed Francisella tularensis as the causative pathogen in testicular tissue. Histological examination revealed dense inflammatory infiltration with histiocytes, neutrophils, and T‑lymphocytes. Combination therapy with doxycycline and ciprofloxacin achieved clinical remission, although fluoroquinolone-induced peripheral neuropathy necessitated treatment modification.

conclusionPatients receiving tumor necrosis factor alpha inhibitors demonstrate increased susceptibility to tularemia manifestations and potential disease relapse. The blood-testis barrier may limit antibiotic penetration, contributing to treatment failure with monotherapy. Enhanced clinical awareness and consideration of combination antimicrobial therapy may be warranted in immunocompromised patients with tularemia, particularly those residing in endemic regions.

Indexed as

AdalimumabNeuropathyOrchitisTNF-alpha InhibitorTularemia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.